Rachna Shroff, MD

Articles

Closing Thoughts on Recent Data in GI Cancers From ESMO 2023

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

November 17th 2023

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.

GASTFOX: Evaluate FOLFOX With or Without Docetaxel (TFOX) as First-Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

November 17th 2023

Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer.

CABINET: Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

November 17th 2023

Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.

Codebreak300: Sotorasib Plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

November 17th 2023

Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.